Akeso (HKSE:09926) Debt-to-Asset : 0.33 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Akeso Debt-to-Asset?

Akeso's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$443 Mil. Akeso's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$2,828 Mil. Akeso's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was HK$10,042 Mil. Akeso's debt to asset for the quarter that ended in Dec. 2023 was 0.33.

Akeso Debt-to-Asset Historical Data

The historical data trend for Akeso's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Debt-to-Asset Chart

Akeso Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.09

0.05

0.18

0.34

0.33

Akeso Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial						0.18	0.27	0.34	0.28	0.33

Competitive Comparison of Akeso's Debt-to-Asset

For the Biotechnology subindustry, Akeso's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akeso's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Akeso's Debt-to-Asset falls into.

Akeso Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Akeso's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(443.01	+	2828.375)	/	10042.082
	=	0.33

Akeso's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(443.01	+	2828.375)	/	10042.082
	=	0.33

Akeso (HKSE:09926) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Akeso Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Akeso's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso (HKSE:09926) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

AKESF:USA 4RY:Germany

Address

6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437

Website

https://www.akesobio.com

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Akeso (HKSE:09926) Headlines

No Headlines